Site-of-Service and medical necessity for IV/SC biologics for autoimmune disorders
Defines medical necessity and site-of-service review requirements for specified intravenous and injectable biologic drugs used to treat multiple autoimmune conditions and which members/plans are affected.
Policy Summary
PayerPremera Bluecross
PolicySite-of-Service and medical necessity for IV/SC biologics for autoimmune disorders
Policy CodePolicy N/A
Change TypeMultiple additions and revisions to drug-specific coverage criteria, site-of-service rules, and coding (material changes)
Effective Date07/02/2026
Next Review DateN/A
Key ActionObtain prior authorization using the applicable HCPCS/J/Q code and document diagnosis, prior therapies, and required lab/biopsy evidence per the agent-specific criteria.
Added criteria for Vyvgart for generalized myasthenia gravis (AChR antibody positive) and related agents (Vyvgart Hytrulo, Rystiggo); concurrent-use restrictions with several complement and Fc-targeted agents were specified.
Added criteria for Orencia for prophylaxis of acute graft versus host disease (aGVHD).
Added coverage criteria for Filspari (sparsentan), Fabhalta (iptacopan), Vanrafia (atrasentan), Voyxact (sibeprenlimab), and other agents for IgA nephropathy and related kidney indications; UPCR/eGFR thresholds and prior therapy requirements updated.
Updated Tarpeyo UPCR threshold from ≥1.5 g/g to ≥0.8 g/g and revised multiple IgAN UPCR thresholds to align with 2025 KDIGO guidance; Voyxact thresholds updated effective July 2, 2026.
Added numerous adalimumab and infliximab biosimilars to coverage with preferred/non-preferred status updates and step therapy sequencing; removed Idacio (adalimumab-aacf) after market removal.
Expanded site-of-service review to include injection drugs and added site-of-service review for Saphnelo, Vyvgart, Vyvgart Hytrulo, and Rystiggo; clarified site-of-service exceptions for Alaska fully-insured members.
Multiple changes effective 07/02/2026: Voyxact eligibility refinements (UPCR >=0.5 g/g or urine protein >=0.5 g/day; eGFR >=30; dialysis/transplant exclusions) and added site-of-service review for Rystiggo.
~20
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
listed drugs subject to site-of-service review (partial list)
~20+biologic/specialty drugs listed in this excerpt
07/02/2026Next batch effective
12 monthstypical approval duration
>=10coverage additions/updates
Age limits specifiedage-based eligibility noted
Coverage Criteria and Medical Necessity
Site-of-service review
We will review specific IV and injectable drugs for medical necessity; for individuals aged 13 years and older we will also review site of service.
Site-of-service review applies: Specified IV and injectable biologics will be reviewed for medical necessity for all ages; site-of-service medical necessity review applies for individuals aged 13 years or older.age >=13
Site of service defined as hospital-based outpatient, infusion center, physician's office, or home
Preferred medically necessary sites: Physician's office, infusion center, or home infusion (when home-infusion criteria are met) are preferred medically necessary sites for specified drugs.
Preferred sites per policy
Hospital-based outpatient medically necessary exceptions: Hospital-based outpatient setting is considered medically necessary for the initial course of infusion/injection or re-initiation after >=6 months for the first 90 days.first 90 days or re-initiation after >=6 months
Does not include standard dosing intervals of 6 months or longer
Hospital necessary for access or increased risk: Hospital-based outpatient setting is medically necessary when no outpatient infusion center exists within 50 miles and no contracted home infusion agency will travel, or when the individual has clinical conditions that increase infusion risk (examples: symptomatic cardiac arrhythmia, significant respiratory disease/%FVC <=40%, unstable renal function, difficult vascular access, acute cognitive impairment impacting safety, history of severe adverse drug reactions/anaphylaxis).distance <=50 miles and specified clinical risk conditions
Also applies for treatment-induced cytokine release syndrome meeting grade 3-4 physiologic criteria
Medically necessary site-of-service criteria and exceptions
Covered when ALL of the following site determinations are met:
Preferred site of administration: Medication administered in physician's office, infusion center, or at home (if home infusion criteria are met).
Preferred medically necessary sites
Hospital outpatient initial/re-initiation exception: Hospital-based outpatient setting is considered medically necessary for the first 90 days for the initial course of infusion/injection or for re-initiation after >=6 months following discontinuation.first 90 days or re-initiation after >=6 months
Excludes standard dosing intervals of 6 months or longer
Hospital medically necessary for access or risk: Hospital site is medically necessary when no outpatient infusion center within 50 miles and no contracted home infusion agency will travel, or when clinical conditions increase infusion risk (e.g., symptomatic cardiac arrhythmia, severe respiratory disease, %FVC <=40%, unstable renal function, difficult vascular access, cognitive impairment affecting safety, prior severe anaphylaxis).
Indication-specific medical necessity
Agent- and indication-specific medical necessity (examples — each agent has detailed, agent-specific criteria):
Hidradenitis suppurativa (adalimumab products): Individual aged >=12 years; tried at least one other therapy (e.g., intralesional/oral corticosteroids or systemic antibiotics); medication prescribed by or in consultation with a dermatologist.age >=12
Managed under pharmacy benefit for listed products
Pyoderma gangrenosum and dermatologic TNF-alpha uses: Individual aged >=18 years; inadequate response to one standard non-biologic therapy; medication prescribed by or in consultation with a dermatologist; some infliximab approvals require prior inadequate response to preferred infliximab biosimilars.age >=18 + prior therapy failure
Agent-specific sequences detailed per drug
Non-infectious intermediate/posterior/panuveitis: Individual aged >=2 years; tried periocular/intraocular/systemic corticosteroids or immunosuppressives; inadequate response or intolerance to specified adalimumab biosimilars as required; medication prescribed by or in consultation with an ophthalmologist.
Considered medically necessary when ALL of the following are met:
Age requirement: Individual is aged 18 years or older.age >=18
Pyoderma gangrenosum criteria
Prior non-biologic therapy: Has not responded to one standard non-biologic therapy (examples: oral corticosteroids, systemic cyclosporine, topical tacrolimus).
Failure/intolerance to conventional therapy required
Preferred infliximab biosimilar failure for some infliximab agents: Has had an inadequate response or intolerance to Avsola (infliximab-axxq) AND Inflectra (infliximab-dyyb) when required by agent-specific sequencing.
Applies to some infliximab product approvals
Non-infectious intermediate/posterior/panuveitis – anti-TNF and infliximab agents
Agent-specific covered when ALL criteria below are met (examples):
Age threshold: Individual is aged 2 years or older.age >=2
Uveitis criteria
Prior therapy: Has tried periocular, intraocular, or systemic corticosteroids OR immunosuppressives.
Required prior therapy before biologic
Adalimumab biosimilar failure (when required): Has had an inadequate response or intolerance to specified adalimumab unbranded agents (examples: Cyltezo, Hyrimoz, Simlandi, Yuflyma) as required by benefit management.
Vyvgart Hytrulo may be considered medically necessary when ALL criteria are met:
Age: Individual is aged 18 years or older.age >=18
CIDP criterion for Vyvgart Hytrulo
Diagnostic criteria: Progressive or relapsing motor and/or sensory symptoms in more than one limb with hyporeflexia/areflexia present for >=2 months; other causes excluded; supportive testing provided if available (CSF, MRI, nerve biopsy).symptom duration >=2 months
Diagnostic support (CSF, MRI, nerve studies) recommended
Prior IV/SCIG trial: Has tried and had an inadequate response or intolerance to intravenous or subcutaneous immunoglobulin (IVIG/SCIG).
Prior IG required before Vyvgart Hytrulo
Recurrent pericarditis – Arcalyst (rilonacept)
Arcalyst may be considered medically necessary when ALL criteria are met:
Age: Individual is aged 12 years or older.age >=12
Recurrent pericarditis age threshold
Prior acute pericarditis: Documented prior episode of acute pericarditis with typical pleuritic chest pain and at least one objective sign (fever, pericardial rub, ECG changes, new/worsening effusion).
Objective signs required
Inflammation evidence: Elevation of inflammatory markers OR imaging evidence of pericardial inflammation on CMR/CT after at least a 4-week symptom-free interval.
Objective inflammation or imaging required
Chronic graft versus host disease (cGvHD) – Niktimvo, Rezurock, Orencia
Agents for chronic graft versus host disease (cGvHD) have agent-specific requirements:
Niktimvo core criteria: Individual weighs at least 40 kg; tried and had an inadequate response or intolerance to at least two prior systemic therapies; prescribed by or in consultation with oncologist/hematologist or transplant center physician; dose limited to 35 mg every 2 weeks.weight >=40 kg; >=2 prior therapies
Agent- and dose-specific limits apply
Rezurock core criteria: Individual aged 12 years or older; tried and had an inadequate response or intolerance to at least two systemic treatments; prescribed by or in consultation with oncologist/hematologist or transplant center physician; dose limited to 200 mg daily.age >=12; >=2 prior therapies
Agent-specific dose limit
Orencia for aGVHD prophylaxis: Individual aged 2 years or older undergoing allogeneic HSCT from specified donor types; will receive calcineurin inhibitor and methotrexate per trial schedules; prescribed by or in consultation with transplant-affiliated physician.
Generalized myasthenia gravis – Imaavy, Rystiggo
Agent-specific criteria when ALL are met:
Age and serology: Imaavy: aged >=12 years; Rystiggo: aged >=18 years; diagnosis of generalized myasthenia gravis with serologic testing for anti-AChR or anti-MuSK antibodies.agent-specific age; positive serology
Agent age limits and serology requirements
Pyridostigmine requirement: Currently using pyridostigmine, has tried and had an inadequate response or intolerance to pyridostigmine, or has contraindication to pyridostigmine.
Acetylcholinesterase inhibitor trial or intolerance
Immunosuppressive therapy requirement: Currently using two or more immunosuppressive therapies (ISTs), has tried and had inadequate response or intolerance to two ISTs, or has contraindications preventing use of two ISTs.2 ISTs
Prior pyridostigmine: Currently using acetylcholinesterase inhibitor (pyridostigmine) or tried and had inadequate response/intolerance or contraindication.
Immunosuppressive therapy: Currently using two or more immunosuppressive therapies or tried and had inadequate response/intolerance to two ISTs or has contraindications preventing use of two ISTs.2 ISTs
Prior biologic trials for AChR-positive MG: For AChR antibody positive MG, tried and had inadequate response or intolerance to at least one listed agent (e.g., eculizumab, ravulizumab, efgartigimod) depending on requested therapy.prior listed biologic trial
Primary IgA Nephropathy – Agent-specific criteria
Covered when ALL of the following are met
Diagnostic and lab requirements: Age >=18 years; documented biopsy-proven primary IgA nephropathy; documented UPCR meeting agent-specific threshold (examples: >=0.5 g/g or >=1.5 g/g depending on agent); eGFR and dialysis/transplant status as required per agent.biopsy + UPCR +/- eGFR
Agent-specific UPCR and eGFR thresholds apply
Prior RAAS therapy: Has tried a maximally tolerated dose of an ACE inhibitor or ARB with persistent UPCR above threshold OR has intolerance to ACEi/ARB.ACEi/ARB trial or intolerance
Maximally tolerated RAAS inhibitor trial required
Prior agent failure when required: Has tried and had an inadequate response or intolerance to listed comparators (e.g., Filspari (sparsentan) or Tarpeyo (budesonide)) when required by agent-specific sequencing.
Sarcoidosis – TNF-α antagonists and infliximab group
Covered when ALL of the following are met
Sarcoidosis core requirements: Individual aged >=18 years; tried and had an inadequate response or intolerance to one corticosteroid and to one immunosuppressive medication (examples: methotrexate, leflunomide, azathioprine, mycophenolate, cyclosporine); medication prescribed by or in consultation with a pulmonologist, ophthalmologist, or dermatologist.prior steroid + immunosuppressant
Specialist involvement required
Second-line biologic escalation: For second-line biologic agents, documentation of inadequate response or intolerance to all listed first-line biosimilar adalimumab products or infliximab biosimilars is required per specific agent criteria.exhausted listed biologics
Some agents require failure of specific biosimilars before approval
Benefit assignment and age/site-of-service requirement
Coverage and benefit assignment rules:
Benefit assignment: Specific agents are assigned to the medical benefit, pharmacy benefit, or both as listed; prior authorization and coverage follow the managing benefit.
See agent lists for benefit assignment
Site-of-service age limit: For site-of-service medical necessity review, individuals must be 13 years of age or older.>=13 years
Applies to site where drug is administered
Clinical trial support (informational)
Clinical evidence summaries (informational) — trial-aligned eligibility and endpoints referenced:
Hidradenitis suppurativa evidence: Phase 3 HS trials demonstrated HiSCR responses with adalimumab (Humira) and secukinumab (Cosentyx) showing HiSCR50 superiority versus placebo in specific regimens; HiSCR defined as >=50% reduction in abscess and inflammatory nodule count with no increase in abscesses or draining fistula count.
Trials referenced: HS Studies I/II and Cosentyx HS Trials
Systemic lupus erythematosus evidence: Belimumab demonstrated SRI improvements in Phase III BLISS trials; pediatric Benlysta trial showed numerical SRI benefit and reduced severe flares; anifrolumab (Saphnelo) met BICLA in TULIP-2 but TULIP-1 failed SRI-4 primary endpoint—trial-aligned severity measures (e.g., SELENA-SLEDAI >=6) are used for authorization decisions.SELENA-SLEDAI >=6; SLEDAI-2K >=6
TULIP-2 BICLA and BLISS trial outcomes summarized
Benlysta (belimumab) pediatric efficacy signals
Covered when ALL of the following align with trial populations and demonstrated benefit:
Benlysta pediatric criteria: Diagnosis of SLE per ACR/EULAR-ACR or SLICC criteria; active disease with SELENA-SLEDAI >=6 at screening; positive autoantibodies as in adult trials; on a stable standard-of-care regimen.SELENA-SLEDAI >=6
Pediatric trial showed numerically higher SRI-4 and reduced severe flare risk
Anifrolumab (Saphnelo) SLE criteria
Covered when ALL of the following reflect trial populations showing benefit in TULIP-2:
Anifrolumab criteria: Adult SLE meeting ACR/EULAR-ACR or SLICC criteria with moderate-to-severe disease (SLEDAI-2K >=6 and clinical SLEDAI2K >=4); on stable standard therapy; trial-aligned endpoints (BICLA) used to demonstrate benefit.SLEDAI-2K >=6; clinical SLEDAI2K >=4
TULIP-2 met BICLA primary endpoint; TULIP-1 did not meet SRI-4
Pyoderma gangrenosum biologic escalation
Covered when ALL of the following are met:
Pyoderma biologic escalation: Diagnosis of pyoderma gangrenosum with inadequate response to first-line topical or systemic immunosuppressive therapies (examples: corticosteroids, azathioprine, cyclosporine, methotrexate, mycophenolate) OR contraindication to these therapies; biologic therapy considered for refractory disease.failure/intolerance to conventional therapy
Biologics (including TNF inhibitors) used in refractory PG
Vasculitis and GCA considerations
Covered when aligning with FDA‑approved indications and trial populations:
Rituximab in WG/MPA: Diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis requiring induction with rituximab plus glucocorticoids per FDA indication.FDA-approved indication
Rituximab approved with glucocorticoids for WG/MPA
Tocilizumab in GCA: Diagnosis of giant cell arteritis consistent with trial inclusion and safety monitoring for infections given higher infection rates in GCA trials.clinical diagnosis of GCA
Covered when ALL of the following match trial populations and demonstrated endpoints:
Imaavy criteria: Adult generalized myasthenia gravis consistent with trial enrollment; evidence of MG‑ADL improvement per Vivacity-MG3; specialist-prescriber as required.trial-aligned population
Vivacity-MG3 supported approval
Uplizna criteria: Adult anti-AChR Ab+ gMG meeting MGFA class II–IV and MG‑ADL/QMG thresholds consistent with trial inclusion; stable immunosuppressive regimen at baseline.MG‑ADL and QMG thresholds per trial
MINT trial outcomes referenced
Vyvgart (IV/Hytrulo) criteria: Adult gMG meeting MG‑ADL and MGFA class II–IV inclusion criteria; treatment cycles and response definitions per ADAPT (MG‑ADL responder = >=2‑point reduction sustained 4 weeks).
Agent-specific covered indications
Covered when ALL of the following are met for the specific agent and indication as supported by cited studies:
Vyvgart/Vyvgart Hytrulo for gMG: Adults with generalized myasthenia gravis who are anti‑AChR antibody positive; supported by phase 3 ADAPT and bridging studies demonstrating IgG reduction and clinical score improvements; Hytrulo is SC formulation with noted increased injection-site reactions.adult; anti-AChR Ab+
Agent-specific trial evidence cited
Rystiggo for gMG: Adults with gMG who are anti‑AChR or anti‑MuSK Ab+ supported by Phase 3 MycarinG showing greater MG‑ADL reduction versus placebo; monitor for common AEs (headache, infections, diarrhea, fever, hypersensitivity, nausea).adult; anti-AChR or anti-MuSK Ab+
Trial-supported efficacy and AE profile noted
Orencia for aGVHD prophylaxis: Recipients >=6 years undergoing allogeneic HSCT receiving calcineurin inhibitor and methotrexate per trial schedules (Days -1, 5, 14, 28) as prophylaxis; demonstrated improved overall and GVHD-free survival in trials; monitor for EBV/CMV reactivation for 6 months post-transplant.
Summary of newly added or revised coverage groups
Covered when ALL of the following agent-specific requirements are met (summary of notable changes/additions):
Filspari (sparsentan) for IgAN: Adult with primary IgA nephropathy at risk for progression; has tried and had inadequate response or intolerance to a maximally tolerated dose of ACE inhibitor or ARB; prescribed by or in consultation with a nephrologist.ACEi/ARB trial
Added coverage criteria per 2023–2025 updates
Vyvgart Hytrulo concurrent-use and added indications: Coverage added for adult gMG and CIDP in specified situations; concurrent-use prohibitions apply versus Vyvgart, Rystiggo, Soliris, Ultomiris, Zilbrysq, Imaavy, and some eculizumab products; brand-specific step therapy may apply.concurrent-use prohibited
Concurrent-use restrictions added
Tarpeyo threshold revision: Tarpeyo urine protein-to-creatinine ratio threshold revised to >=0.8 g/g or proteinuria >=1 g/day in 2025 updates.
Summary of Added Coverage Criteria
Summary of added coverage criteria and policy updates (historical highlights):
Policy additions overview: Multiple drugs and indications were added with coverage criteria (examples include Uplizna, Vyvgart, Saphnelo, Filspari, Tarpeyo, Rystiggo, Voyxact, Fabhalta, Vanrafia, Imaavy, Rezurock, Niktimvo, Bimzelx, Rinvoq); many entries include age, prior therapy, or co-therapy requirements documented in their agent-specific sections.
See individual drug sections for exact criteria
Voyxact Initial Therapy
Covered when ALL of the following are met for Voyxact (sibeprenlimab-szsi):
Voyxact initial coverage: Documented biopsy-proven primary IgA nephropathy; UPCR >= 0.5 g/g OR urine protein >= 0.5 g/day; eGFR >= 30 mL/min/1.73 m2; not on dialysis or post-transplant; tried and had inadequate response or intolerance to Filspari (sparsentan) or Tarpeyo (budesonide); prescribed by or in consultation with a nephrologist.UPCR >=0.5 g/g OR urine protein >=0.5 g/day; eGFR >=30
Effective July 2, 2026 update; prior comparator trial required
Benlysta (belimumab) Age Criterion
Covered when patient meets the age requirement:
Benlysta age for active lupus nephritis: Patient is aged 5 years or older for active lupus nephritis (Benlysta IV/SC).age >=5
Revised from 18 to 5 years per policy updates
Site-of-Service and Concurrent Therapy Restrictions
Coverage restricted by site-of-service review or concurrent therapy rules:
Site-of-service review applies to injections: Site of Service Medical Necessity criteria can apply to injection drugs; site-of-service review was added for Saphnelo (anifrolumab), Vyvgart (efgartigimod), Vyvgart Hytrulo (efgartigimod + hyaluronidase), and Rystiggo (rozanolixizumab).
Effective per history updates
Concurrent therapy exclusions: Certain biologics are prohibited from concurrent use with specified agents (examples: Vyvgart products, Imaavy, Rystiggo, eculizumab products, Ultomiris, Zilbrysq, Uplizna); refer to agent-specific sections for exact prohibited combinations.
Concurrent-use prohibitions specified per agent
Note on applicability for Alaska fully‑insured members: The Site‑of‑Service medical necessity review described in this policy does not apply to Alaska fully‑insured members. For those members, only the infusion and injection drug medical necessity criteria (drug‑specific clinical requirements) should be used; site‑of‑service rules (hospital outpatient vs infusion center/office/home determinations) are not applied. Providers should verify plan‑specific applicability using the member’s plan booklet or ID card when treating Alaska fully‑insured members.
Fabhalta (iptacopan) is excluded for individuals with rapidly progressive crescentic glomerulonephritis. Specifically, Fabhalta is not appropriate when there is clinical evidence of rapidly progressive disease such as a ≥50% decline in eGFR over 3 months accompanied by crescents in ≥50% of glomeruli, or when interstitial fibrosis/tubular atrophy (IF/TA) exceeds 50%. These exclusions are part of the Fabhalta C3G criteria that require biopsy‑proven C3G and specified UPCR and eGFR thresholds for eligible patients.
All other uses of the listed agents beyond the conditions and combinations specifically described in this policy (or in the related policies cited herein) are considered investigational. That includes using two or more of the named biologic agents concurrently or treating indications not explicitly outlined in this policy or the referenced companion policies; such requests do not meet the policy’s coverage criteria.
Clinical trials of belimumab excluded individuals with severe renal or central nervous system (CNS) lupus manifestations, therefore evidence of efficacy in those populations is limited. As noted in the product trial summaries, patients with severe renal or CNS SLE were not evaluated in the Phase III studies, and the label cautions that efficacy in these subgroups is unknown. Coverage decisions should reflect that trial populations did not include these severe renal or CNS disease presentations.
Billing Codes, HCPCS/J/Q and Drug Identifiers
Drugs subject to site-of-service review (partial list)mixed
Prior Authorization, Documentation, and Step Therapy
Prior Authorization
Site-of-service prior authorization — Specified IV and injectable biologics
Specified IV and injectable biologics listed in this policy are subject to site-of-service prior authorization and medical necessity review prior to coverage. Providers must request site-of-service review when administration is planned in a hospital-based outpatient setting, infusion center, or when home infusion is unavailable. Services provided at hospital-based outpatient sites will be considered not medically necessary if site-of-service criteria are not met.
Affected products include (examples): Actemra IV, Avsola IV, Avtozma IV/SC, Benlysta IV/SC, Ilaris SC, Inflectra IV, Infliximab (Janssen) IV, Remicade IV, Renflexis IV, Rystiggo, Saphnelo IV, Tofidence IV, Tyenne IV, Uplizna IV, Vyvgart IV, Vyvgart Hytrulo SC
Approvals typically up to 12 months; non-formulary exception reviews may be approved up to 12 months
Billing Rule
Clinical Background and Evidence Summaries
BACKGROUND: Autoimmune disorders are characterized by immune‑mediated inflammation directed against host tissues and encompass diverse conditions referenced in this policy (for example, hidradenitis suppurativa, pyoderma gangrenosum, systemic lupus erythematosus, IgG4‑related disease, graft‑versus‑host disease, myasthenia gravis, and primary IgA nephropathy). Targeted biologic and specialty agents are commonly used when conventional therapies fail or are contraindicated; this policy defines which intravenous and subcutaneous biologics require prior medical necessity review and specifies preferred sites of service (physician office, infusion center, or home infusion when criteria are met) as well as exceptions when hospital‑based outpatient administration is medically necessary (e.g., initial 90‑day course, re‑initiation after ≥6 months, lack of access to outpatient/home infusion within 50 miles, or patient‑specific increased infusion risk).
Definitions and Clinical Measures
inv-119: Site of service — The location where the drug is administered (hospital-based outpatient, infusion center, physician's office, or home).
Site of service definitionThe site of service is the location where the drug is administered (hospital-based outpatient, infusion center, physician's office, or home)
Applies to medical benefit reviewsSite of Service Medical Necessity criteria applies only to medical benefit reviews and not to Alaska fully-insured members
Age for SOS reviewFor individuals aged 13 and older the policy reviews site of service for medical necessity
inv-120: Hospital-based outpatient medically necessary exception (first 90 days) — Hospital outpatient setting is considered medically necessary for the initial course of infusion/injection or re-initiation after ≥6 mont...
Hospital outpatient exception (first 90 days)Hospital outpatient setting is considered medically necessary for the first 90 days for initial course OR re-initiation after ≥6 months
Policy Revision Timeline
2023-01-01 (effective dates noted in text)product & biosimilar additions
Added coverage criteria for Filspari (sparsentan) for IgAN and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for gMG; added multiple adalimumab biosimilars and updated preferred/non-preferred infliximab sequencing (Avsola, Inflectra) with effective date adjustments noted.
2020-10-01added coverage criteria
Added coverage criteria for Uplizna (inebilizumab-cdon) and Enspryng (satralizumab-mwge) for NMOSD and added HCPCS codes Q5121 and J3590 in history entries.
2024-03-01
Policy Summary
PayerPremera Bluecross
PolicySite-of-Service and medical necessity for IV/SC biologics for autoimmune disorders
Policy CodePolicy N/A
Change TypeMultiple additions and revisions to drug-specific coverage criteria, site-of-service rules, and coding (material changes)
Effective Date07/02/2026
Next Review DateN/A
Key ActionObtain prior authorization using the applicable HCPCS/J/Q code and document diagnosis, prior therapies, and required lab/biopsy evidence per the agent-specific criteria.
distance <=50 miles and presence of specified clinical risk
Also includes CRS grade 3-4 physiologic criteria
age >=2 + prior therapy trial
Agent- and benefit-specific failure lists apply
IgG4-related disease (Uplizna): Individual aged >=18 years with biopsy-confirmed IgG4-RD meeting histopathologic criteria, history of >=2-organ involvement, and an IgG4-RD flare treated with glucocorticoid in the last 3 months; prescribed by or in consultation with appropriate specialist.age >=18 + biopsy + histology + recent steroid-treated flare
Subject to site-of-service review
SLE and lupus nephritis (Benlysta, Saphnelo, Lupkynis): Diagnosis confirmed by ACR/EULAR-ACR or SLICC criteria; used as add-on following standard induction therapy; not used concurrently with specified agents; prescribed by or in consultation with rheumatology/nephrology as applicable; lupus nephritis requires class III/IV/V biopsy and no dialysis in past 12 months.diagnostic criteria + treatment context
Prescriber requirement: Medication prescribed by or in consultation with a dermatologist.
Specialist involvement required
Prescriber requirement:
Medication prescribed by or in consultation with an ophthalmologist.
Specialist involvement required
eGFR threshold: Documented estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m2.>= 30 mL/min/1.73 m2
eGFR requirement per Fabhalta criteria
ACEi/ARB trial: Tried ACE inhibitor or ARB with persistent UPCR above threshold OR intolerance to ACE/ARB.
Maximally tolerated ACEi/ARB trial expected
Exclusions and prescriber: Does not have rapidly progressive crescentic glomerulonephritis or IF/TA >50%; prescribed by or in consultation with a nephrologist.
Exclusion for rapidly progressive disease
Prior NSAID or steroid:
Has received prior treatment with an NSAID or corticosteroid unless contraindicated.
Prior conventional therapy required
Prescriber: Prescribed by or in consultation with a cardiologist.
Specialist involvement required
age >=2; HSCT per trial conditions
Specific dosing schedule per trial (Days -1, 5, 14, 28)
Prior biologic/comparator failures for AChR-positive MG: For AChR antibody positive MG, has tried and had an inadequate response or intolerance to at least one listed comparator biologic (examples include eculizumab, ravulizumab, Vyvgart variants) as required by agent-specific sequencing.prior listed biologic trial
Concurrent-use and sequencing rules apply
Concurrency exclusions: Medication is not being used concurrently with specified other agents (examples: eculizumab products, Ultomiris, Uplizna, Vyvgart products, Rystiggo, Zilbrysq) per concurrent-use prohibitions.
Concurrent-use prohibitions specified per policy
Prescriber requirement: Medication prescribed by or in consultation with an appropriate specialist (e.g., neurologist); some agents specify neurologist or transplant-affiliated prescriber.specialist prescriber
Specialist involvement required
Concurrent-use restrictions apply
Prescriber requirement: Medication prescribed by or in consultation with an appropriate specialist (e.g., neurologist).
Specialist involvement required
Agent-specific sequencing and exclusions: Some agents require prior trials of specific agents or biosimilars and prohibit concurrent use with listed biologics (see agent entries).agent-specific
See individual drug criteria for details
prior comparator trial
Some agents require prior trials of sparsentan or budesonide
Prescriber requirement: Medication prescribed by or in consultation with a nephrologist.nephrologist involvement
Some agents limit dose and duration (eg iptacopan 400 mg/day)
MG‑ADL >=5; responder = >=2-point reduction
ADAPT demonstrated significant responder rate; Hytrulo bridged to IV efficacy
Rystiggo criteria: Adults with anti-AChR or anti-MuSK Ab+ gMG consistent with MycarinG trial enrollment; expected MG‑ADL improvement per study results.antibody-positive gMG
MycarinG showed greater MG‑ADL reduction vs placebo
HSCT recipients >=6 years; trial-based dosing
Prescriber and monitoring requirements noted
Sparsentan (Filspari) for IgAN: Adults with biopsy-confirmed primary IgA nephropathy at risk of rapid progression with persistent proteinuria despite maximized RAS inhibitor therapy; supported by PROTECT showing ~49.8% proteinuria reduction at 36 weeks versus irbesartan.age >=18; urine protein >1.0 g/day despite maximized RAS inhibitor
Trial evidence and safety considerations noted
Tarpeyo for IgAN: Adults with biopsy-verified IgAN, eGFR >=35 mL/min/1.73 m2, and proteinuria >=1 g/day (or UPCR >=0.8) on stable maximized RAS inhibitor therapy; Phase 3 NefIgArd reported 34% UPCR reduction at 9 months versus placebo.biopsy confirmation; eGFR >=35; proteinuria threshold; stable RAS inhibitor therapy
Trial-supported efficacy and common adverse effects noted
>=0.8 g/g or >=1 g/day
Threshold revised in 2025 update
Adalimumab/infliximab biosimilar sequencing: Preferred/non-preferred status and required sequencing updated for multiple adalimumab and infliximab biosimilars; some non-preferred products require trial and failure of preferred products prior to approval.trial and failure of preferred products for non-preferred starts
Multiple product status updates 2023–2025
Benlysta pediatric/lupus nephritis age update: Benlysta coverage extended for pediatric individuals 5 years and older for SLE and active lupus nephritis per prescribing information updates.>=5 years
Age requirement updated
CRS-related coverage clarifications: Actemra and certain IL-6 agents coverage clarified for treatment-induced CRS grade 3-4; documentation required and site-of-service review applies for IV forms.grade 3-4 CRS; treatment-induced
CRS exceptions added
Prior authorization depends on benefit-managed agent
Many biologic agents require prior authorization under drug-specific medical necessity criteria and may be managed under the pharmacy benefit, medical benefit, or both. Product-specific assignment affects where providers must obtain authorization. When a drug is managed under the medical benefit, the provider must submit the applicable HCPCS/J-code; when managed under pharmacy, typical pharmacy prior authorization processes apply.
Prior authorization requests must document the diagnosis and relevant severity markers or disease activity scores required by the drug-specific criteria. Lack of required diagnostic or severity documentation may result in denial.
Examples of required severity/diagnostic documentation: SELENA‑SLEDAI or SLEDAI-2K scores for SLE/Benlysta or Saphnelo; biopsy-proven IgAN with baseline UPCR and eGFR for Tarpeyo, Filspari, Fabhalta; AQP4‑IgG positive test, relapse history and EDSS for NMOSD/uplizna; biopsy with IgG4 immunostaining and histopathologic features for IgG4‑RD
Prior Authorization
Adalimumab product PA and formulary note
Adalimumab-class products and biosimilars have product-preference and step requirements that affect prior authorization. For new starts of branded Humira (AbbVie) and certain infliximab brands, prior inadequate response or intolerance to preferred biosimilars/brands may be required. Check member formulary exceptions and custom formulary notes.
Adalimumab products: preferred vs non-preferred status and step edits (see policy notes and formulary IDs); criteria may not apply to specified custom Open/Incentive formularies — verify member plan
Humira (AbbVie) 00074 requires inadequate response/intolerance to a preferred product for new starts
Step Therapy
Infliximab step requirement for new starts
New starts of certain infliximab products (e.g., Remicade, Janssen unbranded) require prior trial and inadequate response or intolerance to preferred infliximab biosimilars (e.g., Avsola) per updated step therapy sequencing. Providers should document prior biosimilar trials.
Avsola moved to preferred first-line infliximab (effective 01/01/2024); Inflectra sequencing updated
Requirement applies to individuals not previously treated with the requested therapy (step applies to new starts)
Billing Rule
Prior authorization and coding updates
Numerous drugs and HCPCS/J-codes have been added or updated in recent policy revisions. Providers must use current, correct codes when submitting requests and include the code corresponding to the administered product on medical benefit requests.
Use unclassified biologics code J3590 only when appropriate and include product name per payer instructions
Denial Risk
Site-of-service denials
Site-of-service denials may occur when requests do not meet the policy's site-of-service medical necessity criteria. Hospital-based outpatient settings are considered not medically necessary for infusion/injectable therapy when criteria are unmet.
Providers should document why hospital outpatient administration is necessary (e.g., lack of outpatient infusion center within 50 miles, no contracted home infusion, or clinical conditions increasing infusion-related risk) to avoid denial
Denial Risk
Age/site-of-service denial risk
Age limits affect applicability of site-of-service criteria. Site-of-service medical necessity review generally applies to individuals aged 13 years and older; pediatric physiologic and care considerations underlie this threshold. Requests for site-of-service medical benefit administration for individuals under 13 may be limited or denied.
Age criterion for site-of-service medical necessity is 13 years or older; verify FDA-approved age indications for each product
Note
Efficacy signal absent in TULIP-1
For anifrolumab (Saphnelo), TULIP-1 did not meet its pre-specified primary endpoint (SRI-4 at 52 weeks); this efficacy signal absence is noted in the evidence summary and may inform coverage considerations.
TULIP-1: primary outcome SRI-4 not met (36% anifrolumab vs 40% placebo, p=0.412); secondary endpoints nominal
Documentation Required
Tarpeyo documentation requirement
Tarpeyo (budesonide) prior authorization requires documentation of biopsy-verified IgAN, baseline eGFR and UPCR or 24‑hour protein, and evidence of stable maximized RAS inhibitor (ACEi/ARB) therapy per updated criteria. UPCR thresholds were updated to ≥0.8 g/g or ≥1 g/day (policy aligned with trial and KDIGO updates).
Required documentation: biopsy confirmation of IgAN; baseline eGFR ≥35 mL/min/1.73 m2 for original approval criteria (confirm current eGFR threshold in product criteria); UPCR ≥0.8 g/g or proteinuria ≥1 g/day; evidence of stable, maximally tolerated RAS inhibitor therapy or documented intolerance
Prior Authorization
Site-of-service and CRS exceptions
An exception to the site-of-service requirements exists for certain individuals receiving treatment for cytokine release syndrome (CRS). For Actemra and other indicated agents treating CRS, documentation confirming a grade 3–4 treatment-induced CRS and justification for the site are required; failure to document the CRS exception may lead to denial.
CRS coverage: grade 3–4 CRS defined by fever ≥38°C, hypotension requiring vasopressors, and hypoxia requiring high-flow oxygen or positive pressure support
CRS exception durations and approvals follow standard non-formulary/authorization timelines (up to 12 months)
Denial Risk
Denial risk if member does not meet updated UPCR/urine protein, eGFR, prior therapy, or transplant/dialysis exclusions
Requests risk denial if the member does not meet updated UPCR/urine protein, eGFR, age, prior therapy, or dialysis/transplant exclusion criteria. Ensure documentation supports numeric thresholds, prior therapy trials, and absence of dialysis or post-transplant status where required.
Common denial triggers: UPCR below policy threshold, eGFR below required minimum, member on dialysis or post-transplant, missing documentation of prior ACEi/ARB maximally tolerated trial, or lack of required prior biologic trials
Documentation Required
IgG4‑RD diagnostic documentation
For Immunoglobulin G4‑Related Disease (IgG4‑RD), authorization requires biopsy-confirmed diagnosis with immunostaining, supportive imaging or elevated IgG4, histopathologic features (meet ≥2 specified histologic findings), history of multi-organ disease, and recent glucocorticoid-responsive flare.
Required biopsy: at least one involved organ with immunostaining confirming IgG4-positive plasma cells
Histopathology: dense lymphoplasmacytic infiltrate with fibrosis, IgG4+/IgG+ ratio >40% and >10 IgG4+ plasma cells/HPF, or storiform fibrosis/obliterative phlebitis
Document an IgG4‑RD flare requiring glucocorticoid in last 3 months
Documentation Required
SLE/lupus nephritis documentation
SLE and lupus nephritis documentation requirements: diagnosis must be confirmed using ACR, EULAR/ACR, or SLICC criteria; for lupus nephritis, Benlysta or Saphnelo use must be add-on to standard induction therapy (mycophenolate, cyclophosphamide, azathioprine or other immunosuppressant) plus corticosteroid, and concurrent use with certain agents (e.g., Saphnelo with Gazyva) is restricted.
Age: Benlysta SC/IV eligible from age 5 years and older for active lupus nephritis per updated criteria; confirm age for drug-specific indications
Documentation: confirm diagnostic criteria used (ACR, EULAR/ACR, or SLICC) and that standard induction therapy was provided
Documentation Required
Fabhalta required documentation
Fabhalta (iptacopan) requires documentation for C3G indications: biopsy-proven C3G, UPCR threshold per product criteria, baseline eGFR requirement (e.g., ≥30 mL/min/1.73 m2), and evidence of prior ACEi/ARB maximally tolerated trial or intolerance; prescriber should be a nephrologist.
Fabhalta specifics: biopsy-proven C3G; UPCR ≥1 g/g (policy varies by indication—confirm current threshold); eGFR ≥30 mL/min/1.73 m2; prescriber/nephrology consult required
Documentation Required
NMOSD and CIDP diagnostic documentation
For NMOSD and CIDP indications, authorization requires disease-specific diagnostic testing and clinical history: NMOSD requires positive AQP4‑IgG, core clinical characteristics, relapse history, and EDSS score limits; CIDP requires exclusion of alternative causes and supporting test results (e.g., CSF protein elevation, MRI or nerve biopsy findings) and prior IV/SC immunoglobulin trial.
NMOSD: positive AQP4‑IgG, at least 1 relapse in last 12 months or 2 relapses in last 24 months, EDSS ≤7.5, exclusion of MS and other diagnoses
CIDP: exclude infections/toxins/hereditary causes; provide supportive CSF, MRI, or biopsy data; document prior inadequate response/intolerance to IV/SCIG
Documentation Required
Required documentation
Medical records submitted must document that medical necessity criteria are met, including office visit notes with diagnosis, relevant history, physical exam, medication history, prior therapy trials and responses, lab/imaging/biopsy reports, and disease activity scores where applicable.
Include date-stamped clinic notes, documentation of prior therapies and intolerances, objective labs (UPCR, eGFR), pathology reports, relevant antibody test results (e.g., AQP4‑IgG), and disease activity scores (e.g., SLEDAI, SELENA-SLEDAI)
Billing Rule
Coding and benefit assignment
Providers must submit the applicable HCPCS/J/Q code corresponding to the administered biologic for medical benefit requests and indicate benefit assignment (medical vs pharmacy). Incorrect or missing coding may delay review or result in denial.
When product is managed under pharmacy, follow pharmacy PA procedures; when managed under medical, submit appropriate HCPCS/J-code
Documentation Required
Supporting clinical documentation
Supporting clinical documentation must align with the indication-specific criteria (e.g., SLE activity scores for belimumab/anifrolumab, antibody positivity for gMG/NMOSD, biopsy and UPCR/eGFR for IgAN/C3G). Incomplete clinical support increases risk of denial.
Match documentation to the drug's required criteria: provide SELENA‑SLEDAI/SLEDAI-2K for SLE; MG-ADL or AChR-Ab status for gMG therapies; biopsy reports and UPCR/eGFR for IgAN/C3G therapies
Documentation Required
IgAN baseline documentation
For IgAN baseline documentation, include biopsy confirmation of IgAN, baseline eGFR, UPCR or 24‑hour protein values, documentation of maximally tolerated ACEi/ARB trial (or intolerance), prior therapy trials (e.g., Filspari, Tarpeyo), and confirmation of not being on dialysis or post-transplant when required.
Baseline labs: UPCR thresholds per product (e.g., Fabhalta, Filspari, Tarpeyo—policy updated values vary by agent), eGFR minimums (commonly ≥30 mL/min/1.73 m2), and absence of dialysis/post-transplant status
Documentation Required
CRS documentation and exception duration
For Actemra and other agents used to treat cytokine release syndrome (CRS), documentation must confirm CRS diagnosis and grade (3–4) and note if CRS is treatment-induced. Site-of-service exceptions for CRS must be documented. Non-formulary exception authorizations may be approved up to 12 months.
CRS definition: grade 3–4 criteria include fever ≥38°C, hypotension requiring vasopressors, hypoxia requiring high-flow oxygen or positive pressure support
Document that CRS is treatment-induced (not limited to CAR-T) when asserting the CRS exception to site-of-service rules
Documentation Required
Documentation should support UPCR or urine protein values, age, prior therapies
Documentation submitted for IgAN/renal and other proteinuria-based indications should explicitly support UPCR or 24‑hour urine protein values, eGFR, age where applicable, prior therapies tried (including maximally tolerated ACEi/ARB), and any prior biologic or targeted therapy trials and outcomes.
Ensure lab reports include date and numeric values for UPCR (g/g) or 24‑hour protein, and eGFR (mL/min/1.73 m2). Provide documentation of prior ACEi/ARB dosing and response or intolerance.
Step Therapy
Step therapy/failed therapy requirements
Step therapy for TNF‑α antagonists applies across several indications (e.g., pyoderma gangrenosum, hidradenitis suppurativa, uveitis). Many adalimumab-class agents require prior failure of standard non-biologic therapies and sometimes failure of preferred adalimumab biosimilars before non-preferred agents are authorized.
Examples: HS and PG require prior non-biologic therapy (e.g., corticosteroids, antibiotics) and dermatology prescription/consultation; uveitis criteria require trial of periocular/systemic corticosteroids or immunosuppressives and failure of preferred adalimumab products
Step Therapy
Step therapy requirements and gaps
Step therapy specifics vary by indication; some conditions (e.g., generalized myasthenia gravis) require trials of multiple classes (pyridostigmine, two immunosuppressives) prior to biologics. Other off‑label autoimmune uses may not have explicit step edits.
gMG: trial of pyridostigmine and two immunosuppressive therapies required before certain biologics; miscellaneous autoimmune/ off-label uses: step therapy may not be specified — assess case-by-case
Step Therapy
Biologics after conventional therapy
For many rare or refractory autoimmune conditions, biologic therapy is typically considered after failure of conventional topical, systemic corticosteroid, or immunosuppressive therapies. Document prior conventional therapy attempts and outcomes.
Pyoderma gangrenosum example: first-line topical/systemic corticosteroids and immunosuppressants prior to biologic TNF inhibitors
Step Therapy
Biosimilar sequencing
The policy specifies preferred and non-preferred sequencing for biosimilars (adalimumab and infliximab classes). Providers may be required to trial preferred biosimilars (e.g., Avsola for infliximab) before non-preferred branded agents are authorized.
Biosimilar sequencing changes effective 01/01/2024 and later: Avsola moved to preferred infliximab; Inflectra moved to non-preferred sequencing—verify current preferred list before submission
Step Therapy
ACE inhibitor/ARB and adalimumab step therapy
For certain IgAN agents (Filspari, Fabhalta) and other renal therapies, members must have tried and had an inadequate response or intolerance to a maximally tolerated ACE inhibitor or ARB prior to authorization, unless ACEi/ARB intolerance is documented.
Document maximally tolerated ACEi/ARB dosing and persistent UPCR/proteinuria above policy thresholds; note exceptions if intolerance is documented
Step Therapy
Step therapy updates for adalimumab/infliximab products
Recent step therapy updates changed adalimumab and infliximab sequencing (moving certain biosimilars between preferred and non-preferred tiers) and updated infliximab trial requirements for uveitis and other indications. Providers must follow the updated sequencing when documenting prior failed therapies.
Examples: Avsola moved to first-line preferred infliximab (01/01/2024); Inflectra sequencing adjusted; infliximab non-preferred brands require prior trial of preferred infliximab products for new starts
Step Therapy
Step therapy requirements updated for Filspari, Fabhalta, Voyxact and related agents
Step therapy requirements for recent policy updates (e.g., Filspari, Fabhalta, Voyxact) now explicitly require trial of a maximally tolerated ACE inhibitor or ARB and updated UPCR/eGFR thresholds. Ensure documentation reflects these updated thresholds and trial details.
Policy effective dates (2025–07–02 and 2026–07–02) include updated UPCR thresholds (some agents 0.5–0.8 g/g), eGFR minimums (commonly ≥30 mL/min/1.73 m2), and ACEi/ARB maximal tolerated trial requirement
Preferred medically necessary sitesPhysician's office, infusion center, or home infusion (when criteria met) are preferred medically necessary sites
Access and risk-based hospital necessityHospital necessary when no outpatient infusion center within 50 miles and no contracted home infusion agency will travel, or when patient has clinical risk increasing infusion complications
inv-121: UPCR — Urine protein-to-creatinine ratio, used here with threshold ≥ 1 g/g for Fabhalta eligibility.
UPCR definition and useUrine protein-to-creatinine ratio (UPCR) used as a laboratory threshold; policy cites UPCR ≥1 g/g for Fabhalta eligibility in C3G
Documentation requirementBaseline UPCR values must be documented to support medical necessity for agents with UPCR thresholds
Variability by agentUPCR thresholds vary by agent and indication (examples: 0.5, 0.8, 1.0, 1.5 g/g cited across criteria)
inv-122: EDSS — Expanded Disability Status Scale; numeric upper limits specified for NMOSD eligibility (<=7.5 or <=6.5 depending on agent).
EDSS explanationExpanded Disability Status Scale (EDSS) used to limit eligibility in NMOSD criteria; numeric upper limits specified (eg ≤7.5 or ≤6.5 depending on agent)
NMOSD diagnostic contextEDSS used alongside relapse history and AQP4‑IgG status for NMOSD agent eligibility (e.g., Enspryng, Uplizna)
Specialist prescriberNMOSD therapies require specialist prescribing/consultation and documentation of core clinical characteristics
inv-123: Generalized myasthenia gravis coverage criteria — Requires age threshold (typically ≥18, some agents ≥12), serologic confirmation (AChR or MuSK), prior use or intolerance to pyridostigmin...
gMG core requirementsGeneralized myasthenia gravis criteria require age thresholds (typically ≥18; some agents ≥12), serologic confirmation (AChR or MuSK), prior/present use of pyridostigmine and two immunosuppressive therapies (or documented intolerance), and specialist prescriber involvement
Antibody-positive subgroupsMany agents require AChR or MuSK antibody positivity for trial-aligned eligibility and benefit (eg Uplizna, Rystiggo)
Concurrent-use prohibitionsPolicy specifies concurrent-use exclusions versus certain biologics (eg eculizumab products, Vyvgart variants) for some gMG agents
inv-124: Primary IgA nephropathy (IgAN) coverage criteria — Requires biopsy-proven diagnosis, specific UPCR thresholds (≥0.5 g/g or ≥1.5 g/g depending on agent), prior ACEi/ARB therapy or intoleran...
IgAN essential elementsPrimary IgA nephropathy criteria require biopsy-proven diagnosis, agent-specific UPCR thresholds (eg ≥0.5 g/g or ≥1.5 g/g), prior ACEi/ARB trial or intolerance, nephrologist prescriber involvement, and agent-specific eGFR/dialysis/transplant limits
Step therapy with RAS inhibitorsRequirement to have tried a maximally tolerated ACE inhibitor or ARB with persistent proteinuria above agent threshold or documented intolerance
Dose/duration limitsSome IgAN agents have dosing limits (eg iptacopan ≤400 mg/day) and duration limits (eg Vanrafia ≤9 months)
inv-125: IBMTR Severity Index for Acute Graft versus Host Disease — A staging table describing skin, liver, and gastrointestinal involvement with thresholds for rash extent, bilirubin levels, and diarrhea ...
IBMTR Severity Index purposeIBMTR Severity Index provides staging thresholds for acute graft-versus-host disease across skin, liver, and GI involvement to grade severity
Liver/GI thresholdsBilirubin and diarrhea volume thresholds provided in µmol/L and ml/day respectively for staging (see IBMTR table)
inv-126: HiSCR (Hidradenitis Suppurativa Clinical Response) — Defined as at least a 50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in d...
HiSCR definitionHidradenitis Suppurativa Clinical Response (HiSCR) = at least a 50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count relative to baseline
Primary endpoint useHiSCR used as the primary efficacy endpoint at Week 12 in pivotal HS trials (Humira studies)
Interpretation for coverageDocumented HiSCR response in trials supports adalimumab coverage for HS under specified criteria
inv-127: BlyS (BAFF) — B-lymphocyte stimulator, a protein involved in B-cell survival and differentiation; target of belimumab therapy for SLE.
BlyS (BAFF) targetBlyS (BAFF) is B-lymphocyte stimulator, the target of belimumab therapy for SLE
Mechanism relevanceBelimumab binds soluble BlyS to inhibit B-cell survival and differentiation, supporting use in SLE per trial evidence
Trial-based age/score criteriaPediatric Benlysta trials required SELENA‑SLEDAI ≥6 and positive autoantibodies consistent with adult trials
inv-128: anifrolumab mechanism — Human IgG1κ monoclonal antibody binding IFNAR1 to inhibit type I interferon signaling and downstream inflammatory gene expression.
Anifrolumab mechanismAnifrolumab (Saphnelo) is a human IgG1κ monoclonal antibody that binds IFNAR1 to inhibit type I interferon signaling and downstream inflammatory gene expression
Trial endpoint criteriaTULIP-2 trial enrollment and outcomes used SLEDAI‑2K ≥6 and clinical SLEDAI‑2K ≥4 as severity markers for moderate-to-severe SLE
TULIP-1 contextTULIP-1 did not meet SRI‑4 primary endpoint at 52 weeks; evidence base includes mixed trial results warranting trial-aligned documentation
inv-129: FcRn inhibitors / mechanism — Agents (efgartigimod, rozanolixizumab, etc.) reduce circulating IgG by blocking the neonatal Fc receptor (FcRn), promoting IgG catabolism...
FcRn inhibitors mechanismFcRn inhibitors reduce circulating IgG by blocking the neonatal Fc receptor (FcRn), promoting IgG catabolism and lowering pathogenic autoantibodies
Examples of agentsExamples include efgartigimod (Vyvgart, Vyvgart Hytrulo) and rozanolixizumab (Rystiggo)
Clinical effect relevanceFcRn inhibition demonstrated IgG reductions and clinical score improvements in gMG trials (MG‑ADL/QMG endpoints)
inv-130: FcRn inhibitor — A medication that binds the neonatal Fc receptor (FcRn) to reduce recycling of IgG and lower circulating IgG levels; examples include efg...
FcRn inhibitor definitionA medication that binds the neonatal Fc receptor (FcRn) to reduce recycling of IgG and lower circulating IgG levels; examples include efgartigimod formulations and rozanolixizumab
Clinical implicationsLowering IgG can reduce pathogenic autoantibodies in diseases like gMG, supporting agent-specific eligibility criteria
Administration formatsFcRn inhibitors available as IV or SC formulations with agent-specific dosing and site-of-service review considerations
inv-131: Acute GVHD (aGVHD) — Immune-mediated injury occurring typically within 100 days of allogeneic HSCT affecting skin, liver, and GI tract, with manifestations in...
Acute GVHD definitionAcute graft-versus-host disease (aGVHD) is immune-mediated injury typically within 100 days of allogeneic HSCT affecting skin, liver, and GI tract
Clinical manifestationsManifestations include rash, persistent nausea/vomiting, abdominal cramping, and diarrhea; severity staged via IBMTR criteria
Implication for prophylaxis agentsGVHD prophylaxis and treatment agents (eg Orencia) have age and dosing schedules aligned with trial protocols and require transplant-affiliated prescribers
inv-132: CRS — CRS (cytokine release syndrome)
CRS abbreviationCRS = cytokine release syndrome
CRS site-of-service exceptionPolicy includes exception for CRS where hospital-based outpatient setting may be required when CRS is grade 3–4 and physiologic criteria met
CRS-related coverage durationNon-formulary exception review authorizations for CRS-related drugs may be approved up to 12 months per policy update
ACE inhibitor/ARB trial requirementAgents for IgAN commonly require a trial of a maximally tolerated ACE inhibitor or ARB prior to initiating specified agents
Documentation of maximally tolerated dosePolicy clarifies requirement to document maximally tolerated ACEi/ARB dose and persistent proteinuria above threshold or intolerance
Applies to multiple agentsThis requirement is noted for Filspari, Fabhalta, and other IgAN therapies in policy updates
inv-134: UPCR — Urine protein-to-creatinine ratio thresholds specified for coverage decisions (examples updated to ≥0.5 g/g or urine protein ≥0.5 g/day).
Updated UPCR threshold examplesPolicy references updated UPCR thresholds for coverage decisions (examples include ≥0.5 g/g or urine protein ≥0.5 g/day for some agents)
Agent-specific UPCR valuesTarpeyo revised to ≥0.8 g/g (or ≥1 g/day) in 2025; broader policy updates align some agents to ≥0.5 g/g per KDIGO 2025 guidance
Documentation requirementProviders must substantiate UPCR or 24‑hour urine protein values in submitted medical records for eligibility
added/updated criteria
Added coverage criteria for Cosentyx (secukinumab) for hidradenitis suppurativa and updated Vyvgart and related FcRn agent concurrent-use prohibitions; added Tarpeyo and Rezurock criteria.
2026-01-01age-eligibility update
Updated Benlysta (belimumab) SC age requirement for active lupus nephritis from 18 years to 5 years and older.
Voyxact (sibeprenlimab-szsi) initial therapy criteria updated: UPCR threshold lowered to ≥0.5 g/g (or urine protein ≥0.5 g/day), eGFR requirement added (≥30 mL/min/1.73 m2), exclusions for dialysis/post‑transplant added, and prior inadequate response or intolerance to Filspari or Tarpeyo required; site-of-service review for Rystiggo also added in same history entry.